NDLI: Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients

Content Provider	Springer Nature : BioMed Central
Author	Nsiangani Lusambo, Nadine Kaimbo Wa Kaimbo, Dieudonné Ngoyi Mumba, Dieudonné Mumba de-la-Torre, Alejandra
Abstract	Background Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP/SMX) has been presented as an attractive alternative to the “classic’ treatment therapy (Pyrimethamine/Sulfadiazine). Methods A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients. Results 54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment. Conclusion TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.
Related Links	https://bmcophthalmol.biomedcentral.com/counter/pdf/10.1186/s12886-023-03183-x.pdf
Ending Page	8
Page Count	8
Starting Page	1
File Format	HTM / HTML
ISSN	14712415
DOI	10.1186/s12886-023-03183-x
Journal	BMC Ophthalmology
Issue Number	1
Volume Number	23
Language	English
Publisher	BioMed Central
Publisher Date	2023-10-31
Access Restriction	Open
Subject Keyword	Ophthalmology Ocular toxoplasmosis Treatment Outcome Trimethoprim/Sulfamethoxazole RD Congo
Content Type	Text
Resource Type	Article
Subject	Ophthalmology
Journal Impact Factor	1.7/2023
5-Year Journal Impact Factor	2/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Treatment Strategy in Human Ocular Toxoplasmosis: Why Antibiotics Have Failed

Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine

Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine

Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.

Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/ Sulfamethoxazole versus Pyrimethamine and Sulfadiazine

Trimethoprim-sulfamethoxazole in the treatment of malaria, toxoplasmosis, and pediculosis.

Oral trimethoprim-sulfamethoxazole in the treatment of cerebral toxoplasmosis in AIDS patients--a prospective study.

Therapy for ocular toxoplasmosis.

Oral trimethoprim-sulfamethoxazole in the treatment of cerebral toxoplasmosis in AIDS patients - a prospective study

Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients

Similar Documents

Treatment Strategy in Human Ocular Toxoplasmosis: Why Antibiotics Have Failed

Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine

Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine

Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.

Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/ Sulfamethoxazole versus Pyrimethamine and Sulfadiazine

Trimethoprim-sulfamethoxazole in the treatment of malaria, toxoplasmosis, and pediculosis.

Oral trimethoprim-sulfamethoxazole in the treatment of cerebral toxoplasmosis in AIDS patients--a prospective study.

Therapy for ocular toxoplasmosis.

Oral trimethoprim-sulfamethoxazole in the treatment of cerebral toxoplasmosis in AIDS patients - a prospective study

Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients